Significant Gap Between Guidelines and Practice in the Management of LDL Cholesterol: Insight From the Survey of the Korean Society of Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38147840/
The Guidelines of the 2019 European Society of Cardiology (ESC) and the 5th Society of Lipid and Atherosclerosis (KSoLA) for the Management of Dyslipidemia advocate a more intensive lipid-lowering strategy....
A substantial disparity exists between lipid management guidelines and current clinical practices, highlighting the necessity for clinical research that specifically targets East Asians and Koreans to bridge this gap.
Share
Glycemic Variability and Time in Range Are Associated With the Risk of Overweight and High LDL-Cholesterol in Children and Youths With Type 1 Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38104553/
CGM metrics of glycaemic control and variability were significantly associated with the risk of overweight in females and high LDL-c in both sexes.
Continuous glucose monitoring metrics of glycemic control and variability were significantly associated with the risk of overweight in girls and high LDL-C in both sexes.
Share
Genetic Insights Into the Association of Statin and Newer Nonstatin Drug Target Genes With Human Longevity: a Mendelian Randomization Analysis
Source : https://lipidworld.biomedcentral.com/articles/10.1186/s12944-023-01983-0
It remains controversial whether the long-term use of statins or newer nonstatin drugs has a positive effect on human longevity. Therefore, this study aimed to investigate the genetic associations between...
Lipid-related gene targets, such as PCSK9, CETP, and APOC3, might potentially regulate human lifespan, thus offering promising prospects for developing newer nonstatin therapies.
Share
Measuring Lipoprotein(a) for Cardiovascular Disease Prevention - In Whom and When?
Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the...
Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.
Share
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
Source : https://link.springer.com/article/10.1007/s11883-023-01166-3
An evidence for lipid lowering therapy in heart failure is briefly summarized in this review. Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and...
PCSK9 inhibitors, new lipid-lowering drugs, are very effective in LDL-C lowering and prevention of ASCVD. The role of PCSK9 inhibitors in HF treatment is investigated.
Share